Dextran conjugated dendritic nanoconstructs as potential vectors for anti-cancer agent
Source abstract
Abstract
The purpose of the present investigation was to evaluate the potential of surface engineered polypropylene imine (PPI) dendrimers as nanoscale drug delivery units for site-specific delivery of a model anti-cancer agent, doxorubicin.hydrochloride (DOX). Dextran conjugated PPI dendrimers were synthesized, characterized and further loaded with DOX. The developed formulation was characterized by Fourier transform infrared spectroscopy (FTIR), nuclear magnetic resonance (NMR) and transmission electron microscopic (TEM) studies. Dendrimer formulation was evaluated for in vitro drug release and haemolytic studies under various pH conditions. Cell uptake and cytotoxicity studies were performed on A549 cell lines using MTT cell proliferation assay. In vivo studies were conducted for evaluation of various pharmacokinetic parameters and tissue distribution pattern. In vitro, formulation displayed initial rapid release of the drug followed by rather slow release. Further, the dextran conjugated dendrimer formulation was found to be least haemolytic but more cytotoxic as compared to free drug. Cell uptake studies depicted that the formulation was preferably taken up by the tumor cells when compared to free drug. The conjugation of oxidized polyaldehyde dextran imparts macromolecular nature to the dendritic carrier, consequently the formulation was found to selectively enter highly porous mass of tumor cells at the same time precluding normal tissues. Thus it was concluded that the drug loaded dendrimer formulation would selectively localize in the tumor mass, increasing the therapeutic margin of safety while reducing the side effects associated with anti-cancer agents.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Dendrimers and Hyperbranched Polymers · RNA Interference and Gene Delivery · Polymer Surface Interaction Studies
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (37)
Show source-provided references
1. Dendrimers in biomedical applications – reflections on the field10.1016/j.addr.2005.09.018 ↗
2. Polymer drug conjugates; recent development for anti-cancer drugs
3. Tumor targeting based on enhanced permeability and retention (EPR) and mechanism of receptor mediated endocytosis (RME)10.1016/j.ijpharm.2003.09.050 ↗
4. A concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumorotropic accumulation of proteins and anti-tumor agents SMANCS
5. Poly(ethylene glycol)-modified gelatin nanoparticles for intracellular delivery
6. Polymer–drug conjugates: towards a novel approach for the treatment of endocrine-related cancer10.1677/erc.1.01045 ↗
7. Site-specific drug delivery10.1002/med.2610070104 ↗
8. Dendrimers as potential delivery systems for bioactives
9. Polyamidoamine (PAMAM) dendritic nanostructures for controlled site specific delivery of acidic anti-inflammatory active ingredients10.1208/pt060367 ↗
10. A review of in vitro–in vivo investigations on dendrimers: the novel nanoscopic carriers10.1016/j.nano.2006.04.002 ↗
11. Micro and nano drug delivery systems in cancer therapy
12. Tumor targeted delivery of dextran–doxorubicin conjugate using chitosan nanoparticles as a carrier10.1016/S0168-3659(01)00342-X ↗
13. DE-310: a novel macromolecular carrier system for the camptothecin analog DX-8951f: potent antitumor activities in various murine tumor models10.1111/j.1349-7006.2004.tb03199.x ↗
14. Investigation of targeting mechanism of new dextran–peptide–methotrexate conjugates using biodistribution study in matrix-metalloproteinase-overexpressing tumor xenograft model10.1002/jps.20548 ↗
15. Potential use of an asparaginase–dextran conjugate in acute lymphoblastic leukaemia10.1111/j.2042-7158.1983.tb02891.x ↗
16. Lysosomotropic agents10.1016/0006-2952(74)90174-9 ↗
17. Polymer conjugates with anticancer activity
18. SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy10.1016/S0169-409X(00)00134-4 ↗
19. Molecular mechanisms for lymphangiogenesis in health disease10.1016/S1535-6108(02)00051-X ↗
20. Recent trends in the use of polysaccharides for improved delivery of therapeutic agents: pharmacokinetic and pharmacodynamic perspectives10.2174/1389201033489685 ↗
21. Devita · 1989
22. Martindale. The Extra Pharmacopoeia Royal Pharmaceutical Society London Pharmaceutical press; 1996;31st ed.:567.
23. The role of anthracyclins in second line therapy of ovarian cancer10.1136/ijgc-00009577-200311001-00009 ↗
24. Poly (propylene imine) dendrimers: large scale synthesis by heterogeneously catalyzed hydrogenation10.1002/anie.199313081 ↗
25. Glycodendrimeric nanoparticulate carriers of primaquine phosphate for liver targeting10.1016/j.ijpharm.2005.01.026 ↗
26. Polysaccharide–oligoamine based conjugates for gene delivery10.1021/jm0105528 ↗
27. Emerging themes in medicinal glycoscience10.1038/78435 ↗
28. Tumor pH-responsive flower-like micelles of poly(l-lactic acid)-b-poly(ethylene glycol)-b-poly(l-histidine)10.1016/j.jconrel.2007.08.006 ↗
29. Evaluation of aqueous suspension of ketoprofen
30. PEGylated dendritic nanoparticulate carrier of fluorouracil10.1016/S0378-5173(03)00132-7 ↗
31. Drug complexation, in vitro release and cellular entry of dendrimers and hyperbranched polymers10.1016/S0378-5173(03)00225-4 ↗
32. Comparison of the sulforhodamine B assay and the clonogenic assay for in vitro chemoradiation studies10.1007/s00280-002-0557-9 ↗
33. Targeting and inhibition of cell growth by an engineered dendritic nanodevice10.1021/jm040187v ↗
34. Pharmacokinetics and biodistribution studies of doxorubicin loaded poly(butylcyanoacrylate) nanoparticles synthesized by two different techniques10.5507/bp.2004.029 ↗
35. Folate-receptor-targeted delivery of doxorubicin nanoaggregates stabilized by doxorubicin–PEG–folate conjugate10.1016/j.jconrel.2004.08.017 ↗
36. Rapid and sensitive HPLC method for the estimation of doxorubicin in dog blood – The silver nitrate artifact
37. Application of dendrimer–drug complexation in the enhancement of drug solubility and bioavailability10.1517/17425255.4.8.1035 ↗